

Chiral resolution of *RS*-oxiracetam upon cocrystallization with pharmaceutically acceptable inorganic salts.

Oleksii Shemchuk,^a Lixing Song,^b Nikolay Tumanov,^c Johan Wouters,^c Dario Braga,^a Fabrizia Grepioni^{*,a} and Tom Leyssens^{*,b}

^a*Molecular Crystal Engineering Laboratory, Dipartimento di Chimica “G. Ciamician”, Università di Bologna, Via F. Selmi 2, 40126 Bologna, Italy, E-mail: fabrizia.grepioni@unibo.it*

^b*Institute of Condensed Matter and Nanosciences, Université catholique de Louvain, 1 Place Louis Pasteur, B-1348 Louvain-La-Neuve, Belgium, E-mail: tom.leyssens@uclouvain.be*


^c*Unité de Chimie Physique Théorique et Structurale, Chemistry Department, Namur Institute of Structured Matter (NISM), University of Namur, 61 rue de Bruxelles, B-5000 Namur, Belgium.*

ABSTRACT

Ionic cocrystals (ICCs) of racemic *RS*-oxiracetam and of its active *S*-enantiomer of pharmaceutical interest with the pharmaceutically acceptable salts calcium and magnesium chloride have been synthesized and structurally characterized. The cocrystallization of *RS*-oxiracetam with MgCl_2 resulted into chiral resolution with formation of a *S*-OXI· MgCl_2 ·5H₂O / *R*-OXI· MgCl_2 ·5H₂O conglomerate. Ternary phase diagrams *RS*-oxiracetam/inorganic salt/solvent have been constructed to determine the overall compositions for which the ICCs are the only stable phases in suspension. In addition, single crystals of *S*-oxiracetam were grown and its structure determined.

INTRODUCTION

Cocrystals in general, and ionic cocrystals (ICCs) in particular, have become attractive research topics in the pharmaceutical industry, since they can provide an alternative route to new pharmaceutical formulations compared to conventional salts.¹⁻⁷ A virtually infinite choice of molecular and/or ionic building blocks makes the number of possible combinations between active pharmaceutical ingredients (APIs) and ancillary co-formers or other APIs limitless. ICCs belong to a class of multicomponent crystalline solids composed of neutral organic molecules and salts in a defined stoichiometric ratio.⁸⁻¹⁵ Pharmaceutical ICCs are of particular interest since they can modulate the physicochemical and biological properties of the APIs (e.g. bioavailability, solubility, intrinsic dissolution rate, morphology, stability towards humidity and thermostability) in an impressive manner.¹⁶⁻²⁰ The formulation of drugs as cocrystals can be especially important with APIs that lack ionizable moieties, therefore cannot be formulated and used as conventional salts. Enantiopure and racemic oxiracetam (scheme 1) investigated in this work belong to such APIs.



Scheme 1. Chemical structure of enantiopure (left) and racemic (right) oxiracetam.

Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidineacetamide, hydroxypiracetam) is a nootropic drug of the racetam family and a very mild stimulant.²¹ It was also tested for potential use in different forms of dementia and it was reported to have no side effects. Oxiracetam showed beneficial effects on logical performance, attention, concentration and memory.²¹⁻²³ Some studies showed that oxiracetam was more effective than the prototype nootropic piracetam.²⁴

Oxiracetam was first synthesized by Smith Kline Beecham Company in 1974 as a racemate.²⁵ However, as typical for the majority of chiral drugs only one enantiomer (*S*-oxiracetam) exerts the desired biological properties.²¹ Therefore, marketing of oxiracetam as a pure enantiomer, in principle, could be interesting. Furthermore, the general trend in the pharmaceutical industry is to evolve toward development of chiral medicines in enantiomerically enriched and ideally pure form.²⁶ However, *S*-oxiracetam was found by Wang et al. to be heavily hygroscopic with deliquescence occurring after a three day hold at 87% RH and 25 °C.²⁵ They successfully tried to enhance the hygroscopic stability of *S*-oxiracetam upon its cocrystallization with gallic and 3,4-dihydroxybenzoic acids.²⁵ Even though the crystal structures of these cocrystals were given in the manuscript,²⁵ the structure of enantiopure oxiracetam has not been reported so far. In the CSD²⁷ only the structure of racemic oxiracetam is available.²⁸

The impact of cocrystallization on the chirality of pharmaceutical compounds has been thoroughly investigated by our research groups. The formation of molecular²⁹ and ionic^{30, 31} cocrystals was found to be a suitable technique to achieve chiral resolution of racemic mixtures. Cocrystallization of the amino acids DL-histidine and DL-proline with lithium halides showed the possibility to perform chiral resolution,^{30, 31} as Li⁺ linked selectively with amino acids of only one chirality, with formation of conglomerates or of racemic crystals but constituted of homochiral chains, while the use of

calcium³² halides led to cocrystallization of racemic ICCs. Chiral resolution was obtained also via coordination of levetiracetam (*S*-etiracetam) and *RS*-etiracetam to ZnCl_2 :³³ in this work chiral resolution was attempted by varying the stoichiometric ratio of the co-former, thus enabling a reversible switch between a thermodynamically stable racemic compound and conglomerate. On the basis of the results concerning the Li^+ and Zn^{2+} cations, it was initially assumed that the tetrahedral geometry around the cation was a prerequisite for the segregation, in individual chains or crystals, of molecules of the same handedness. However, in our latest paper³⁴ we showed that the cocrystallization of etiracetam with both CaCl_2 and MgCl_2 resulted in the formation of homochiral layers of octahedrally coordinated calcium and magnesium cations.

In this paper we explore the effect of cocrystallizing both enantiopure and racemic oxiracetam with, CaCl_2 and MgCl_2 , both pharmaceutically acceptable inorganic salts. Ternary phase diagrams (TPDs) for the system *RS*-oxiracetam /inorganic salt /solvent were constructed, to determine the overall compositions for which the ICCs were the only stable phases in suspension. We furthermore identified conditions for the system *RS*-oxiracetam / MgCl_2 / ethanol 70%, which can be used to develop a resolution by *entrainment* (preferential crystallization).^{35, 36} Crystalline *S*-oxiracetam was also structurally characterized.

EXPERIMENTAL PART

Materials and instrumentation

RS-oxiracetam and *S*-oxiracetam were purchased from Xiamen Top Health Biochem Tech. Co., Ltd All the other reagents were purchased from Sigma and used without further purification.

Single crystals of *S*-oxiracetam of suitable quality for X-ray analysis were grown through evaporation of an acetonitrile solution at 60°C. 10 mg of *S*-oxiracetam were dissolved in 15 mL of acetonitrile upon heating. The solution was left to evaporate at 60°C.

Solution Synthesis. *S*-OXI· CaCl_2 ·5 H_2O , *S*-OXI· MgCl_2 ·5 H_2O and OXI₂· CaCl_2 were obtained by slow evaporation from aqueous solution (3 mL) of stoichiometric quantities (117.5 mg – 41.3 mg for OXI₂· CaCl_2 and 62.4 mg – 37.6 mg for *R*-OXI· MgCl_2 ·5 H_2O / *S*-OXI· MgCl_2 ·5 H_2O) of the reagents (2:1 for OXI₂· CaCl_2 and 1:1 for the rest) at room temperature. The evaporation process over a period of 10-30 days resulted in the formation of an oil-like product.

Slurry synthesis. $\text{OXI}_2 \cdot \text{CaCl}_2$ was also obtained by slurring a stoichiometric amount of oxiracetam and CaCl_2 (235 mg – 82.5 mg) for 2 days at 25°C in 5 mL of absolute ethanol, whereas the conglomerate mixture $R\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$ / $S\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$ was obtained slurring a stoichiometric mixture in 70% ethanol (see the section S4, SI).

Mechanochemical synthesis. $\text{OXI}_2 \cdot \text{CaCl}_2$ and $R\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$ / $S\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$ were obtained mechanochemically by ball-milling stoichiometric ratios of the starting materials (117.5 mg – 41.3 mg for $\text{OXI}_2 \cdot \text{CaCl}_2$ and 62.4 mg – 37.6 mg for $R\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$ / $S\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$) in stainless steel jars for 15 min in a Retsch MM200 ball miller operated at a frequency of 20 Hz, using stainless steel jars (5 mL) and two 3-mm balls, with the addition of a drop of water.

Thermogravimetric analysis. TG analyses were performed with a PerkinElmer TGA7 in the temperature range 40-500 °C under N_2 gas flow at a heating rate of 5.00 °C min⁻¹.

Differential Scanning Calorimetry. DSC thermograms were recorded using a Perkin-Elmer Diamond. The samples (1-3 mg range), obtained via kneading were placed in open Al-pans. All measurements were conducted at a heating rate of 5 or 10°C min⁻¹.

X-ray Diffraction from Powder. For phase identification purposes X-ray powder diffraction (XRPD) patterns were collected on a PANalytical X'Pert Pro Automated diffractometer equipped with an X'celerator detector in Bragg-Brentano geometry, using Cu-K α radiation ($\lambda=1.5418$ Å) without monochromator in 3-50° 2 θ range (step size 0.033°; time/step: 20 s; Soller slit 0,04 rad, antiscatter slit: ½, divergence slit: ¼ ; 40 mA*40kV).

Single Crystal X-ray Diffraction.

S-Oxiracetam

Single-crystal X-ray diffraction data were collected using an Oxford Diffraction Gemini R Ultra diffractometer (Cu K α , multilayer mirror, Ruby CCD area detector) at 295(2) K. Data collection, unit cells determination and data reduction were carried out using CrysAlis PRO software package³⁷ using Olex2³⁸ interface. The structure was solved with the SHELXT 2015³⁹ structure solution program by Intrinsic Phasing methods and refined by full-matrix least squares on $|F|^2$ using SHELXL-2018/3.⁴⁰ Non-hydrogen atoms were refined anisotropically. All hydrogen atoms were located from a Fourier map. Hydrogen atoms, not involved in hydrogen bonding, were placed on calculated positions in riding mode with temperature factors fixed at 1.2 times U_{eq} of the parent carbon atoms. H_{OH} and H_{NH}

atoms were refined riding on their respective nitrogen or oxygen atoms (X-H distances were refined). Absolute configuration of the sample was established by anomalous-dispersion effects in diffraction measurements on the crystal. Flack x parameter determined using 1125 quotients $[(I_+)-(I_-)]/[(I_+)+(I_-)]^{41}$ and equal to 0.07(8).

CaCl₂ and MgCl₂ ICCs.

Single Crystal data were collected at room temperature with an Oxford Diffraction X'Calibur equipped with a graphite monochromator and a CCD detector. Mo-K α radiation ($\lambda = 0.71073$ Å) was used. Unit cell parameters for both complexes discussed herein are reported in Table SI-1. The structure was solved by the Intrinsic Phasing methods and refined by least squares methods against F^2 using SHELXT-2014⁴² and SHELXL-2018⁴⁰ with Olex2 interface.³⁸ Non-hydrogen atoms were refined anisotropically. H_{CH} atoms were added in calculated positions; H_{OH} and H_{NH} atoms were either located from a Fourier map or added in calculated positions and refined riding on their respective carbon, nitrogen or oxygen atoms. The software Mercury 4.0⁴³ and VESTA⁴⁴ were used for graphical representations and for powder patterns simulation on the basis of single crystal data.

Ternary Phase Diagram. TPDs were constructed by slurring oxiracetam with CaCl₂ and MgCl₂ in absolute and 70% ethanol, respectively, varying the molar ratio of the starting materials from 0 to 1. Experiments were carried out in a number of 2 mL sealed vials, and the suspensions were stirred at constant temperature (25°C) for at least 48h. Seeding with all possible solid-state forms was performed to make sure that the system reached thermodynamic equilibrium. Afterwards the samples were filtered by sand core funnel and the obtained solids were characterized by XRPD. To determine the equilibrium compositions required for the determination of the solubility lines, all the experiments described above were repeated up to the filtration step. After slurring for 48h, small portions of solvent were added to the stirring mixtures every 30 minutes, until complete dissolution of the suspended solid was observed. This allowed the construction of the solubility line in the ternary phase diagram. TPDs were drawn with the software ProSim Ternary Diagram. For detailed information see SI.

RESULTS AND DISCUSSION

***S*-oxiracetam**

Single crystals of *S*-oxiracetam suitable for X-ray structure determination were grown from hot acetonitrile, due to the high hygroscopicity of the compound. *S*-oxiracetam (Fig. 1) crystallizes in the

monoclinic $P2_1$ space group with two molecules in the asymmetric unit cell (for detailed structural information on this and the other solids discussed in this paper see table SI-1).




Figure 1. Hydrogen bonding patterns of the type $\text{--NH}\cdots\text{OCO}$ (top) and $\text{--OH}\cdots\text{OCO}$ (bottom) in crystalline *S*-oxiracetam. H_{CH} omitted for clarity.

Cocrystallization of *S*-oxiracetam with CaCl_2 and MgCl_2 (see SI) resulted in the formation of the isomorphous solids $S\text{-OXI}\cdot\text{CaCl}_2\cdot 5\text{H}_2\text{O}$ (Fig. 2) and $S\text{-OXI}\cdot\text{MgCl}_2\cdot 5\text{H}_2\text{O}$ (fig. SI-2).




Figure 2. The crystal packing of $S\text{-OXI}\cdot\text{CaCl}_2\cdot 5\text{H}_2\text{O}$ (top) and a single chain (bottom). Water oxygens in blue; H atoms omitted for clarity.

As it can be seen in Fig. 2, two *S*-oxiracetam molecules and four water molecules are coordinated to the Ca^{2+} cation via the oxygen atoms in an octahedral fashion. The fifth water molecule is hydrogen bonded to the chloride anions and to the water molecules of the first coordination sphere. Each *S*-oxiracetam molecule interacts in turn with a second calcium cation, thus forming infinite chains extending along the crystallographic *b*-axis (see Fig. 2, bottom).

***RS*-oxiracetam**

RS-oxiracetam (oxiracetam hereafter) was also cocrystallized with magnesium and calcium chlorides, and, differently from what observed with the enantiopure *S*-oxiracetam, the use of the two inorganic salts yielded two different products. Oxiracetam formed with CaCl_2 the racemic $\text{OXI}_2 \cdot \text{CaCl}_2$ (fig. 3), which, quite surprisingly, is anhydrous, in contrast to the majority of ICCs obtained with racetams and calcium chloride.^{32, 45} Crystalline $\text{OXI}_2 \cdot \text{CaCl}_2$ is characterized, as in the case of the enantiopure $S\text{-OXI} \cdot \text{CaCl}_2 \cdot 5\text{H}_2\text{O}$, by an octahedral coordination around the calcium cation, but in the racemate four oxiracetam molecules provide all the necessary oxygen atoms to the central calcium cation. As the Ca^{2+} ions are located on inversion centers, the four oxiracetam molecules are divided in two pairs of opposite chirality (2 *R*- and 2 *S*-oxiracetam molecules). Each oxiracetam molecule, in turn, is coordinated to two calcium cations. Once again the coordination to the metal center results in the formation of infinite 1D chains, which extend along the crystallographic *b*-axis direction, as shown in fig. 3.




Figure 3. Packing arrangement of the 1D-chains and the chloride ions in crystalline $\text{OXI}_2 \cdot \text{CaCl}_2$ (top) and a single chain showing the involvement of all oxygen atoms in the coordination to the calcium cations (bottom). H atoms omitted for clarity.

Cocrystallization of oxiracetam with MgCl_2 resulted in spontaneous chiral resolution, with formation of a stable $S\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$ / $R\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O}$ conglomerate. Chiral resolution was observed in all cocrystallization methods applied, whether ball milling with a drop of water, slow evaporation from undersaturated aqueous, ethanol and methanol solutions or by slurry. The cocrystal is always found as a pentahydrate phase. Ternary phase diagrams (TPD) for oxiracetam/ MgCl_2 /ethanol were then determined, which helped to identify the thermodynamically stable equilibrium for different overall compositions at a given temperature and pressure (see Fig. 4 and Fig. SI-16). The choice of the solvent is important for the overall aspect of this diagram, as oxiracetam is almost insoluble in absolute ethanol and extremely soluble in water. A series of experiments were performed to identify the water-ethanol mixture that led to the largest stability zone for the conglomerate suspension. This occurred for a 70% ethanol composition of the solvent. Detailed information on the construction of the given TPD is given in the supporting information.




Figure 4. Enlarged portion of the ternary phase diagram for $RS\text{-oxi} : \text{MgCl}_2 : 70\%\text{-EtOH}$ at 298K (mol%). [For the full version see Fig. SI-17.]

The experimental ternary phase diagram (see Fig. 4 and Fig. SI-17) shows two biphasic regions (**I** = $RS\text{-oxi} + \text{L}$ and **V** = $\text{MgCl}_2 + \text{L}$), one triphasic regions (**III** = $S\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O} + R\text{-OXI} \cdot \text{MgCl}_2 \cdot 5\text{H}_2\text{O} + \text{L}$).

OXI·MgCl₂·5H₂O + L), and two quadriphasic regions (**II** = *RS*-OXI + *S*-OXI·MgCl₂·5H₂O + *R*-OXI·MgCl₂·5H₂O + L and **IV** = MgCl₂ + *S*-OXI·MgCl₂·5H₂O + *R*-OXI·MgCl₂·5H₂O + L); L is the liquid phase. It is worth stressing that these phase diagrams can be used to develop a full resolution by *entrainment* (preferential crystallization),^{35, 36} by targeting the triphasic region **III**, where the conglomerate is the only thermodynamically stable phase in suspension.

Considering *S*-OXI·MgCl₂·5H₂O and *S*-OXI·CaCl₂·5H₂O to be isostructural, a number of attempts were made to try and force conglomerate formation for the *RS*-oxiracetam CaCl₂ system also. Attempts were made by i) introducing seeds of *S*-OXI·MgCl₂·5H₂O / *R*-OXI·MgCl₂·5H₂O (10%) into the oil formed upon evaporation of the undersaturated oxiracetam: CaCl₂ solution, ii) simultaneous cocrystallizing CaCl₂ and MgCl₂ (0.05 mmol + 0.05 mmol) with oxiracetam (0.1 mmol) through slow solvent evaporation, and iii) by carrying out a number of ball milling experiments varying the stoichiometric ratio of CaCl₂/MgCl₂. Unfortunately, none of these experiments yielded formation of a CaCl₂ conglomerate. The ball milling always resulted in the formation of a physical mixture of *S*-OXI·MgCl₂·5H₂O / *R*-OXI·MgCl₂·5H₂O and OXI₂·CaCl₂, whereas crystallization from solution always led to the formation of *S*-OXI·MgCl₂·5H₂O / *R*-OXI·MgCl₂·5H₂O crystals with CaCl₂ and the unreacted oxiracetam remaining in the liquid/oil phase.

CONCLUSIONS

The formation of both molecular and ionic cocrystals represents a promising technique to perform chiral resolution of racemic mixtures. In this work ICCs of both racemic and enantiopure oxiracetam with the pharmaceutically acceptable salts CaCl₂ and MgCl₂ have been obtained and structurally characterized. The cocrystallization of *RS*-oxiracetam with MgCl₂ led to chiral resolution with formation of an *S*-OXI·MgCl₂·5H₂O / *R*-OXI·MgCl₂·5H₂O conglomerate. In these solids the Mg²⁺ cations are octahedrally coordinated, and this is the first observation of chiral resolution achieved by cocrystallization with a metal in this type of coordination. Considering these results and the fact that the cocrystallization of etiracetam with CaCl₂ and MgCl₂ also resulted in formation of homochiral layers around calcium and magnesium cations, it might be concluded that the phenomenon of homochiral preference of metal cations goes beyond the tetrahedral geometry around the metal cation and is driven by even subtler conditions. This study also showed that ternary phase diagrams can be easily constructed allowing identifying those zones where ICCs are the only stable phases in suspension and where entrainment can be performed.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI:xxxx. TGA, DSC, X-ray powder patterns, ternary phase diagrams.

Accession Codes

CCDC 1972456-1972459 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, U.K.; fax: +44 1223 336033.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This material is based on the work of xxx supported by yyy and on the work of O.S., D. B., and F.G., supported by the University of Bologna (RFO scheme).

References

- (1) Almarsson, O.; Zaworotko, M. J., Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? *Chem. Commun.* **2004**, 0, (17), 1889-96.
- (2) Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J., Pharmaceutical co-crystals. *J. Pharm. Sci.* **2006**, 95, (3), 499-516.
- (3) Schultheiss, N.; Newman, A., Pharmaceutical Cocrystals and Their Physicochemical Properties. *Cryst. Growth Des.* **2009**, 9, (6), 2950-2967.
- (4) Yadav, A. V.; Shete, A. S.; Dabke, A. P.; Kulkarni, P. V.; Sakhare, S. S., Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients. *Indian J. Pharm. Sci.* **2009**, 71, (4), 359-70.
- (5) Good, D. J.; Rodriguez-Hornedo, N., Solubility Advantage of Pharmaceutical Cocrystals. *Cryst. Growth Des.* **2009**, 9, (5), 2252-2264.
- (6) Wouters, J.; Quéré, L., *Pharmaceutical salts and co-crystals*. ed.; Royal Society of Chemistry: 2011.
- (7) Jones, W.; Motherwell, W. D. S.; Trask, A. V., Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement. *MRS Bulletin* **2011**, 31, (11), 875-879.
- (8) Braga, D.; Grepioni, F.; Maini, L.; Prosperi, S.; Gobetto, R.; Chierotti, M. R., From unexpected reactions to a new family of ionic co-crystals: the case of barbituric acid with alkali bromides and caesium iodide. *Chem. Commun.* **2010**, 46, (41), 7715-7.
- (9) Smith, A. J.; Kim, S.-H.; Duggirala, N. K.; Jin, J.; Wojtas, L.; Ehrhart, J.; Giunta, B.; Tan, J.; Zaworotko, M. J.; Shytle, R. D., Improving lithium therapeutics by crystal engineering of novel ionic cocrystals. *Mol Pharm* **2013**, 10, (12), 4728-4738.

- (10) Kelley, S. P.; Narita, A.; Holbrey, J. D.; Green, K. D.; Reichert, W. M.; Rogers, R. D., Understanding the effects of ionicity in salts, solvates, co-crystals, ionic co-crystals, and ionic liquids, rather than nomenclature, is critical to understanding their behavior. *Cryst. Growth Des.* **2013**, 13, (3), 965-975.
- (11) Delori, A.; Galek, P. T.; Pidcock, E.; Patni, M.; Jones, W., Knowledge-based hydrogen bond prediction and the synthesis of salts and cocrystals of the anti-malarial drug pyrimethamine with various drug and GRAS molecules. *CrystEngComm* **2013**, 15, (15), 2916-2928.
- (12) Butterhof, C.; Bärwinkel, K.; Senker, J.; Breu, J., Polymorphism in co-crystals: a metastable form of the ionic co-crystal 2 HBz · 1 NaBz crystallised by flash evaporation. *CrystEngComm* **2012**, 14, (20), 6744-6749.
- (13) Wang, T.; Stevens, J. S.; Vetter, T.; Whitehead, G. F. S.; Vitorica-Yrezabal, I. J.; Hao, H.; Cruz-Cabeza, A. J., Salts, Cocrystals, and Ionic Cocrystals of a “Simple” Tautomeric Compound. *Cryst. Growth Des.* **2018**, 18, (11), 6973-6983.
- (14) Linberg, K.; Ali, N. Z.; Etter, M.; Michalchuk, A. A. L.; Rademann, K.; Emmerling, F., A Comparative Study of the Ionic Cocrystals NaX (α -D-Glucose)₂ (X = Cl, Br, I). *Cryst. Growth Des.* **2019**, 19, (8), 4293-4299.
- (15) Kavanagh, O. N.; Walker, G.; Lusi, M., Graph-Set Analysis Helps To Understand Charge Transfer in a Novel Ionic Cocrystal When the ΔpK_a Rule Fails. *Cryst. Growth Des.* **2019**, 19, (9), 5308-5313.
- (16) Duggirala, N. K.; Smith, A. J.; Wojtas, Ł.; Shytle, R. D.; Zaworotko, M. J., Physical stability enhancement and pharmacokinetics of a lithium ionic cocrystal with glucose. *Cryst. Growth Des.* **2014**, 14, (11), 6135-6142.
- (17) Buist, A. R.; Kennedy, A. R., Ionic Cocrystals of Pharmaceutical Compounds: Sodium Complexes of Carbamazepine. *Cryst. Growth Des.* **2014**, 14, (12), 6508-6513.
- (18) Oertling, H., Interactions of alkali- and alkaline earth-halides with carbohydrates in the crystalline state—the overlooked salt and sugar cocrystals. *CrystEngComm* **2016**, 18, (10), 1676-1692.
- (19) Shemchuk, O.; Braga, D.; Maini, L.; Grepioni, F., Anhydrous ionic co-crystals of cyanuric acid with LiCl and NaCl. *CrystEngComm* **2017**, 19, (10), 1366-1369.
- (20) Honer, K.; Kalfaoglu, E.; Pico, C.; McCann, J.; Baltrusaitis, J., Mechano-synthesis of Magnesium and Calcium Salt Urea Ionic Cocrystal Fertilizer Materials for Improved Nitrogen Management. *ACS Sustain Chem Eng* **2017**, 5, (10), 8546-8550.
- (21) Gouliarov, A. H.; Senning, A., Piracetam and other structurally related nootropics. *Brain Res Rev.* **1994**, 19, (2), 180-222.
- (22) Itil, T. M.; Menon, G. N.; Bozak, M.; Songar, A., The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). *Drug Dev. Res.* **1982**, 2, (5), 447-461.
- (23) Dager, S. R.; Loebel, J. P.; Claypool, K.; Case, M.; Budech, C. B.; Dunner, D. L., Oxiracetam in the treatment of primary dementia of the Alzheimer's type: A small case series. *Int. J. Geriatr. Psychiatry* **1992**, 7, (12), 905-912.
- (24) Gallai, V.; Mazzotta, G.; Del Gatto, F.; Montesi, S.; Mazzetti, A.; Dominici, P.; Della Monica, A., A clinical and neurophysiological trial on nootropic drugs in patients with mental decline. *Acta neurologica* **1991**, 13, (1), 1-12.
- (25) Wang, Z. Z.; Chen, J. M.; Lu, T. B., Enhancing the Hygroscopic Stability of S-Oxiracetam via Pharmaceutical Cocrystals. *Cryst. Growth Des.* **2012**, 12, (9), 4562-4566.
- (26) Nunez, M. C.; Garcia-Rubino, M. E.; Conejo-Garcia, A.; Cruz-Lopez, O.; Kimatrai, M.; Gallo, M. A.; Espinosa, A.; Campos, J. M., Homochiral drugs: a demanding tendency of the pharmaceutical industry. *Curr. Med. Chem.* **2009**, 16, (16), 2064-74.
- (27) Groom, C. R.; Bruno, I. J.; Lightfoot, M. P.; Ward, S. C., The Cambridge Structural Database. *Acta Crystallogr B Struct Sci Cryst Eng Mater* **2016**, 72, (Pt 2), 171-9.
- (28) Bandoli, G.; Grassi, A.; Nicolini, M.; Pappalardo, G. C., Solid-State Structure and Conformation of the Nootropic Agent 4-Hydroxy-2-Oxo-1-Pyrrolidineacetamide - X-Ray and

Theoretical Self-Consistent Field Molecular-Orbital (Scf-Mo) Studies. *Chem. Pharm. Bull. (Tokyo)* **1985**, 33, (10), 4395-4401.

(29) Springuel, G.; Leyssens, T., Innovative Chiral Resolution Using Enantiospecific Co-Crystallization in Solution. *Cryst. Growth Des.* **2012**, 12, (7), 3374-3378.

(30) Braga, D.; Degli Esposti, L.; Rubini, K.; Shemchuk, O.; Grepioni, F., Ionic Cocrystals of Racemic and Enantiopure Histidine: An Intriguing Case of Homochiral Preference. *Cryst. Growth Des.* **2016**, 16, (12), 7263-7270.

(31) Shemchuk, O.; Tsenkova, B. K.; Braga, D.; Duarte, M. T.; André, V.; Grepioni, F., Ionic Co-crystal Formation as a Path Towards Chiral Resolution in the Solid State *Chem. Eur. J.* **2018**, in press.

(32) Shemchuk, O.; Esposti, L. D.; Grepioni, F.; Braga, D., Ionic co-crystals of enantiopure and racemic histidine with calcium halides. *CrystEngComm* **2017**, 19, (42), 6267-6273.

(33) Shemchuk, O.; Song, L.; Robeyns, K.; Braga, D.; Grepioni, F.; Leyssens, T., Solid-state chiral resolution mediated by stoichiometry: crystallizing etiracetam with ZnCl₂. *Chem. Commun.* **2018**, 54, (77), 10890-10892.

(34) Song, L.; Shemchuk, O.; Robeyns, K.; Braga, D.; Grepioni, F.; Leyssens, T., Ionic Cocrystals of Etiracetam and Levetiracetam: The Importance of Chirality for Ionic Cocrystals. *Cryst. Growth Des.* **2019**, 19, (4), 2446-2454.

(35) Collet, A.; Brienne, M. J.; Jacques, J., Optical resolution by direct crystallization of enantiomer mixtures. *Chemical Reviews* **1980**, 80, (3), 215-230.

(36) Levilain, G.; Coquerel, G., Pitfalls and rewards of preferential crystallization. *CrystEngComm* **2010**, 12, (7), 1983.

(37) CrysAlisPRO, Oxford Diffraction /Agilent Technologies UK Ltd, Yarnton, England.

(38) Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H., OLEX2: a complete structure solution, refinement and analysis program. *J Appl Crystallogr* **2009**, 42, (2), 339-341.

(39) Sheldrick, G. M., SHELXT - integrated space-group and crystal-structure determination. *Acta Crystallogr. A Found. Adv.* **2015**, 71, (Pt 1), 3-8.

(40) Sheldrick, G. M., Crystal structure refinement with SHELXL. *Acta Crystallogr. C Struct. Chem.* **2015**, 71, (Pt 1), 3-8.

(41) Parsons, S.; Flack, H. D.; Wagner, T., Use of intensity quotients and differences in absolute structure refinement. *Acta Crystallogr B Struct Sci Cryst Eng Mater* **2013**, 69, (Pt 3), 249-59.

(42) Sheldrick, G. M., SHELXT– Integrated space-group and crystal-structure determination. *Acta Crystallogr. A Found. Adv.* **2015**, 71, (1), 3-8.

(43) Macrae, C. F.; Edgington, P. R.; McCabe, P.; Pidcock, E.; Shields, G. P.; Taylor, R.; Towler, M.; van De Streek, J., Mercury: visualization and analysis of crystal structures. *J Appl Crystallogr* **2006**, 39, 453-457.

(44) Momma, K.; Izumi, F., VESTA 3 for three-dimensional visualization of crystal, volumetric and morphology data. *J Appl Crystallogr* **2011**, 44, 1272-1276.

(45) Song, L. X.; Robeyns, K.; Leyssens, T., Crystallizing Ionic Cocrystals: Structural Characteristics, Thermal Behavior, and Crystallization Development of a Piracetam-CaCl₂ Cocrystallization Process. *Cryst. Growth Des.* **2018**, 18, (5), 3215-3221.